Neha Patil (Editor)

AryoGen

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Industry
  
Pharmaceutical

Website
  
AryoGen

Revenue
  
100 million USD

Number of employees
  
300

Area served
  
Worldwide

Headquarters
  
Tehran

Founded
  
2009

Type
  
Privately held company

AryoGen ecth2016orgwpcontentuploads201601Aryogen30

Key people
  
Dr. Fereidoun Mahboudi Chairman

Products
  
biopharmaceuticals, Monoclonal antibody

Aryogen biopharma tehran iran


AryoGen Pharmed (in Persian: آریوژن فارمد ) is an Iranian biopharmaceutical company specializing in manufacturing Therapeutic Monoclonal antibodies and some other recombinant proteins.

Contents

History

AryoGen is a biopharmaceutical company created on the mandate of Iranian executive branch. It was created a group of scientific experts spun off a well versed Biopharmaceutical company, which formed a totally new entity christened as AryoGen Biopharma which started its production in 2011. It was deemed an issue of national interest due to the importance of the target products on Iran's community health care system, as well as its impact in the region and around the world.

AryoGen is the world's first company to produce biosimilar Blood Coagulation Factor VII, which required a 50 million Euros product investment. Also AryoGen has established a monoclonal antibodies production line amongst only 10 manufacturer of the world.

AryoGen has been change his name to AryoGen Pharmed since 2016.

Products

AryoGen's products include:

  • Blood Coagulation factor VII with the name of AryoSeven which is a biosimilar form of Novoseven with multi billion dollars world market and is used for hemophilia patients and other conditions
  • Altebrel with the generic name of Etanercept and original trade name of Enbrel which for some years was the no. one in the biopharmaceutical market and is used for treatment of autoimmune diseases
  • Zytux with the generic name of Rituximab and original trade name of Rituxan which is an anticancer biomedicine,
  • Hercease with the generic name of trastuzumab and original name of Herceptin which is a revolutionary drug in treatment of breast cancer
  • Arvestin with the generic name of bevacizumab and original trade name of Avestin and is used for treatment of some sort of cancer.

    • AryoSeven is now approved by Iranian food and drug organisation and from Aug 2012 is in the market and other biomedicines are closing to the market.

    References

    AryoGen Wikipedia
    (Text) CC BY-SA


    Similar Topics